콘텐츠로 이동

BRCA 또는 PALB2 결핍 전이성 췌장암 환자를 대상으로 한 vilastobart와 retifanlimab 병용 요법의 2상 임상시험

Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC

안내

이 페이지는 자동 수집·AI 요약된 정보입니다. 의료 조언이 아니며, 치료 결정은 반드시 담당 의료진과 상의하세요. 응급 상황은 응급 가이드 또는 119.

항목 내용
등록번호 NCT07765836
상태 모집 예정
단계 2상
시험 약물/중재 vilastobart (XTX101), Retifanlimab
대상 질환 Pancreatic Cancer Metastatic
스폰서 Massachusetts General Hospital
연령·성별 18 Years ~ 제한 없음 · ALL
목표 인원 40
시작 / 1차 완료 예정 2027-01 / 2028-12-31
국내 실시기관 없음
실시 국가 1개국, 기관 1곳 (United States)
결과 게시 아니오
최근 갱신 2026-08-14

문의처 (등록된 중앙 연락처)

  • Harshabad Singh, MBBS MD 617-724-4000 sharshabad@mgb.org

국내 기관 참여 문의는 해당 병원 임상시험센터 또는 담당 주치의를 통해 하세요. 참여 방법 안내

시험 개요

이 임상시험은 BRCA1, BRCA2 또는 PALB2 유전자 결핍이 있는 전이성 췌장암(pancreatic cancer) 환자를 대상으로 합니다. Fc 강화 CTLA-4 항체인 vilastobart와 PD-1 항체인 retifanlimab을 병용 투여하는 단일군, 공개 형태의 다기관 2상 임상시험입니다. 연구의 주요 목적은 객관적 반응률(objective response rate, ORR)을 통해 이 병용 요법의 유효성을 평가하는 것입니다. 목표 환자 수는 최대 40명이며, 환자들은 최대 1년 동안 치료를 받고 최대 3년 동안 추적 관찰을 받게 됩니다.

  • 대상 질환은 BRCA1, BRCA2 또는 PALB2 유전자 변이가 있는 전이성 췌장암입니다.
  • 시험 치료는 면역항암제 병용 요법인 vilastobart와 retifanlimab입니다.
  • 주요 평가지표는 객관적 반응률(ORR)입니다.
  • 목표 등록 환자 수는 최대 40명입니다.

참여 조건 (AI 정리, 원문 확인 필요)

선정 기준: - 조직학적으로 확진된 전이성 췌장암 환자 (선상세포암, 선암, 도관선암, 저분화암 또는 선역사선암 포함) - CLIA 인증 검사로 종양 차세대 염기서열 분석(NGS)을 통해 BRCA1, BRCA2 또는 PALB2의 생식세포 또는 체세포 병원성 변이가 확인된 환자 - RECIST 버전 1.1에 따른 측정 가능한 병변 보유 - 안전한 생검이 가능한 병변이 최소 1개 이상 있으며 치료 전후 생검에 동의한 환자 - 전이성 질환에 대해 세포독성 항암화학요법을 1~2차례 받았던 환자 - 최소 1회 이상 백금 기반 항암화학요법을 받았고 최소 안정 병변(stable disease) 이상의 반응을 보였던 환자 (백금 치료 시 질병이 진행된 경우는 제외) - 연령 18세 이상 - ECOG 수행 상태 0~2 - 적절한 골수 및 장기 기능을 충족하는 환자 - B형간염 바이러스(HBV) 또는 C형간염 바이러스(HCV) 감염 환자의 경우 조건 충족 시 참여 가능 - 피임 지침을 준수할 수 있는 남녀 환자

제외 기준: - 췌장 신경내분비종양 환자 - 이전에 anti-CTLA-4 치료 또는 anti-PD-1/PD-L1 면역관문억제제 치료를 받은 적이 있는 환자 - 연구 치료 시작 전 2주 이내 또는 반감기 5배 이내에 승인된 전신 항암 치료를 받은 환자 - 연구 치료 시작 전 2주 이내에 방사선 치료를 받은 환자 - 이전 항암 치료로 인한 독성에서 회복되지 않은 환자 (탈모 또는 안정적인 2등급 이하의 말초신경병증 제외) - 연구 참여를 방해할 수 있는 조절되지 않는 동반 질환이 있는 환자 - 연구 요구사항 준수를 제한할 수 있는 정신 질환이나 사회적 상황이 있는 환자 - 적극적인 감염 치료가 필요한 환자

선정/제외 기준 원문 (영어)

Inclusion Criteria:

  • Participant must have histologically proven metastatic pancreatic cancer. Histologies including acinar cell carcinoma, carcinoma, ductal carcinoma, ductal adenocarcinoma, poorly differentiated or adenosquamous carcinoma are allowed.
  • Participant must have a germline or somatic pathogenic alteration in BRCA1, BRCA2, or PALB2 on tumor next generation sequencing (NGS) performed using a CLIA certified assay. Somatic pathogenic alterations detected on circulating tumor DNA need confirmation on tumor tissue NGS. Germline pathogenic alterations in BRCA1, BRCA2 or PALB2 do not require further confirmation on tumor NGS. All genomic reports be verified in writing (via email) by site and/or overall PI.
  • Participants must have measurable disease per RECIST version 1.1.
  • Participant must have at least one disease site which is amenable to safe biopsy and must agree to pre- and on-treatment biopsies (core, incisional, or excisional biopsy) of tumor site. In select cases biopsies can be waived after discussion with the Sponsor Investigator.
  • Participant must have had at least one but not more than two lines of cytotoxic chemotherapy for metastatic disease. Receipt of neoadjuvant or adjuvant therapy within the last 12 months may count as one line of therapy in metastatic setting for patients with recurrent disease who are being considered for the study. Receipt of targeted therapy such as KRAS inhibitor, or PARP inhibitor is not counted line of therapy. Recycling of the same agents from prior lines of cytotoxic chemotherapy after disease progression does not count as a new line of therapy.
  • Participant must have had prior platinum containing chemotherapy with at least a best response of stable disease. Participants with primary disease progression on platinum chemotherapy are ineligible.
  • Age ≥18 years
  • ECOG performance status of 0-2.

  • Participants must meet the following organ and marrow function as defined below:

  • absolute neutrophil count ≥1,000/mcL

  • platelets ≥75,000/mcL
  • total bilirubin ≤ 1.5x institutional upper limit of normal (ULN). For patients with liver metastases or confirmed/suspected Gilbert syndrome, total bilirubin ≤ 3 × ULN
  • AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN. For patients with liver metastases, AST and ALT ≤ 5 × ULN
  • glomerular filtration rate (GFR) ≥30 mL/min/1.73 m\^2
  • For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. For participants with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
  • It is not known what effects study treatment has on human pregnancy or development of the embryo or fetus. Therefore, female patients participating in this study should avoid becoming pregnant, and male patients should avoid impregnating a female partner. Non-sterilized female patients of reproductive age group and male patients should use effective methods of contraception through defined periods during and after study treatment as specified below:

Female patients must meet 1 of the following:

  • Postmenopausal for at least 1 year before the screening visit, or
  • Surgically sterile, or

  • Women of childbearing potential must:

  • agree to practice 1 effective method of contraception from the time of signing of the informed consent form through 5 months after the last dose of study drug.

  • Agree not to breastfeed from the time of signing of the informed consent form through 5 months after the last dose of study drug
  • Have a serum or urine pregnancy test to rule out pregnancy within 2 weeks prior to registration.
  • Male patients must agree to practice 1 effective method of contraception from the time of signing of the informed consent form through 7 months after the last dose of study drug.

Highly effective methods of contraception include:

  • Sexual abstinence (no sexual intercourse)
  • Hormonal birth control
  • Intrauterine device (IUD) or intrauterine system (IUS)
  • Bilateral tubal ligation (both tubes tied)
  • Vasectomy - Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • Participants with neuroendocrine tumors of the pancreas are excluded.

  • Prior anticancer therapy:

  • Received prior treatment with anti-CTLA-4 therapy

  • Received prior immune-checkpoint anti-PD-1/PD-L1 therapy
  • Received prior approved systemic anticancer therapy within 2 weeks or within its 5 half-lives prior to study treatment, whichever is shorter. Note: Long-standing hormonal therapy for prostate, breast, uterine, and adrenal cancer may be permitted to continue if it is deemed to be in the best interest of the patient, after discussion with the Sponsor Investigator.
  • Received prior radiotherapy within 2 weeks prior to study treatment. Note: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-CNS disease
  • Participants who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia or stable, Grade ≤ 2 non-autoimmune chemotherapy-induced peripheral neuropathy.
  • Participants with uncontrolled intercurrent illness that would interfere with ability to participate in the opinion of the treating investigator.
  • Participants with psychiatric illness/social situations that would limit compliance with study requirements.
  • Has an active infection requiring systemic intravenous or oral therapy within 7 days of cycle 1 day 1.
  • Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial treatment. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. COVID-19 vaccination should not be given within 7 days of trial drug initiation.

  • Active autoimmune disease requiring systemic immunosuppression in excess of physiologic maintenance doses of corticosteroids (> 10 mg/day of prednisone or equivalent).

  • Physiologic corticosteroid replacement therapy at doses ≤ 10 mg/day of prednisone or equivalent for adrenal or pituitary insufficiency and in the absence of active autoimmune disease is permitted.

  • Participants with asthma that requires intermittent use of bronchodilators, inhaled corticosteroids, or local corticosteroid injections may participate.
  • Participants using topical, ocular, intra-articular, or intranasal corticosteroids (with minimal systemic absorption) may participate.
  • Brief courses of corticosteroids for prophylaxis (eg, contrast dye allergy) or study treatment-related standard premedications are permitted.
  • Replacement therapy (e.g. thyroxine, insulin) is not considered a form of systemic therapy and is allowed.
  • Has a history of immune-related (non-infectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease regardless of etiology.
  • Subjects with any condition requiring systemic treatment with either corticosteroids (>10mg/day of prednisone or equivalent) or other immunosuppressive medications within 14 days of treatment. Premedication for hypersensitivity reactions (e.g. to contrast for CT or gadolinium for MRI) or for prophylaxis of infusion related reactions is allowed.

Exceptions: use of inhaled, intranasal, intraocular, topical, and intraarticular joint injections are allowed

  • Participants with a known history of Human Immunodeficiency Virus (HIV) infection are excluded unless they meet all of the following criteria:

  • Stable antiretroviral therapy (ART) for at least 12 weeks prior to enrollment

  • No history of AIDS-defining conditions.
  • CD4+ T-cell count ≥ 350 cells/mm\^3 at screening
  • HIV viral load ≤ 50 copies/mL at screening.
  • No significant comorbidities associated with HIV infection that could interfere with the safety or efficacy of the investigational treatment.
  • No concurrent use of prohibited medications that may interfere with the study drug or cancer therapy
  • Has a history of severe hypersensitivity reaction (≥ Grade 3) to any study intervention and/or any of its excipients (refer to the IBs and/or approved product label for a list of excipients)
  • Participants with brain metastases (active brain metastases) or leptomeningeal disease are not eligible. Patients with treated brain metastases who are off systemic steroids > 2 weeks and have documented radiographic stability over 4 weeks since initial brain metastasis diagnosis may be considered in discussion with the Sponsor Investigator.
  • Has a history of allogeneic bone marrow/stem, cell or solid organ transplantation.
  • Unstable angina, myocardial infarction, congestive heart failure (New York Heart Association [NYHA] classification ≥ grade 2) or unstable vascular disease (eg, aortic aneurysm at risk of rupture, Moyamoya disease) that required hospitalization within 6 months prior to randomization, or other cardiac impairment that may affect the safety evaluation of the study drug (eg, poorly controlled arrhythmias, myocardial ischemia).

출처: ClinicalTrials.gov · 수집 2026-10-06 · 갱신 2026-10-06

댓글 기능은 아직 설정 전입니다 (관리자: docs/SETUP.md의 giscus 항목 참고). 의견은 GitHub Discussions에 남겨 주세요.